Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Eptinezumab Humanized Recombinant Human Monoclonal Antibody
Human Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA542119
This item is not returnable.
View return policy
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. 7 Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). 8, 1, 2, 3 It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.
Specifications
Eptinezumab Humanized | |
Recombinant Monoclonal | |
Unconjugated | |
ALD-403 | |
Human CALCA /CALCB. | |
100 μg | |
Primary | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid | |
Chemical |
ELISA, SDS-Page | |
1.61 mg/mL | |
PBS with no preservative; pH 7.4 | |
Human | |
Protein A/G | |
RUO | |
Human | |
Antibody | |
IgG1 κ |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction